Find Desoxycorticosterone Pivalate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

JP

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

14 RELATED EXCIPIENT COMPANIES

31EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 808-48-0, Deoxycortone pivalate, Docp, Desoxycortone pivalate, Dtma, Deoxycorticosterone pivalate
Molecular Formula
C26H38O4
Molecular Weight
414.6  g/mol
InChI Key
VVOIQBFMTVCINR-WWMZEODYSA-N
FDA UNII
16665T4A2X

Desoxycorticosterone Pivalate
Desoxycorticosterone pivalate is a mineralocorticoid hormone and an analog of desoxycorticosterone. It is white, odorless, and stable in air. It is practically insoluble in water, sparingly soluble in acetone, slightly soluble in methanol, ether and vegetable oils. Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.
1 2D Structure

Desoxycorticosterone Pivalate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[2-[(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate
2.1.2 InChI
InChI=1S/C26H38O4/c1-24(2,3)23(29)30-15-22(28)21-9-8-19-18-7-6-16-14-17(27)10-12-25(16,4)20(18)11-13-26(19,21)5/h14,18-21H,6-13,15H2,1-5H3/t18-,19-,20-,21+,25-,26-/m0/s1
2.1.3 InChI Key
VVOIQBFMTVCINR-WWMZEODYSA-N
2.1.4 Canonical SMILES
CC12CCC3C(C1CCC2C(=O)COC(=O)C(C)(C)C)CCC4=CC(=O)CCC34C
2.1.5 Isomeric SMILES
C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)COC(=O)C(C)(C)C)CCC4=CC(=O)CC[C@]34C
2.2 Other Identifiers
2.2.1 UNII
16665T4A2X
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Deoxycortone Pivalate

2. Desoxycoticosterone Trimethylacetate

3. Percoten Pivalate

2.3.2 Depositor-Supplied Synonyms

1. 808-48-0

2. Deoxycortone Pivalate

3. Docp

4. Desoxycortone Pivalate

5. Dtma

6. Deoxycorticosterone Pivalate

7. 11-deoxycorticosterone Pivalate

8. Deoxycortone Trimethylacetate

9. Desoxycorticosterone Trimethylacetate

10. Deoxycorticosterone Trimethylacetate

11. 11-deoxycorticosterone, Pivalate

12. Neodin-depositum

13. Cortexone M

14. Percorten M

15. 11-deoxy Corticosterone Pivalate

16. Percorten Pivalate

17. Desoxycorticosteronepivalate

18. Chebi:50782

19. Desoxycorticosterone Pivalate (usp)

20. Desoxycorticosterone Pivalate [usp]

21. 3,20-dioxopregn-4-en-21-yl 2,2-dimethylpropanoate

22. 16665t4a2x

23. Pregn-4-ene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-

24. [2-[(8s,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 2,2-dimethylpropanoate

25. Percorten V

26. Percorten (tn)

27. Nsc 95278

28. 21-(2,2-dimethyl-1-oxopropoxy)pregn-4-ene-3,20-dione

29. Nsc-95278

30. Unii-16665t4a2x

31. 3,20-dioxopregn-4-en-21-yl Pivalate

32. Ncgc00159355-02

33. Einecs 212-366-0

34. Zycortal

35. Brn 3174879

36. Desoxycorticosterone-pivalate

37. Dsstox_cid_26036

38. Dsstox_rid_81301

39. Dsstox_gsid_46036

40. 4-08-00-02196 (beilstein Handbook Reference)

41. Schembl120007

42. Chembl1200592

43. Dtxsid8046036

44. Corticosterone, Deoxy-, Pivalate

45. Zinc4082455

46. Tox21_111599

47. Akos032428733

48. Desoxycortone Pivalate [mart.]

49. Db01134

50. Desoxycortone Pivalate [who-dd]

51. Ncgc00160511-01

52. Cas-808-48-0

53. Desoxycorticosterone Pivalate [mi]

54. Hy-107917

55. Cs-0030864

56. Desoxycorticosterone Pivalate [vandf]

57. Desoxycorticosterone Trimethyl Acetate

58. Desoxycorticosterone Pivalate [usp-rs]

59. D03699

60. 808d480

61. A839987

62. Desoxycorticosterone Pivalate [green Book]

63. Desoxycorticosterone Pivalate [orange Book]

64. Desoxycorticosterone Pivalate [usp Monograph]

65. Desoxycortone Pivalate [ema Epar Veterinary]

66. W-104224

67. Q27092729

68. [2-[(8s,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]-2-oxo-ethyl] 2,2-dimethylpropanoate

2.4 Create Date
2006-11-09
3 Chemical and Physical Properties
Molecular Weight 414.6 g/mol
Molecular Formula C26H38O4
XLogP34.5
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count4
Rotatable Bond Count5
Exact Mass414.27700969 g/mol
Monoisotopic Mass414.27700969 g/mol
Topological Polar Surface Area60.4 Ų
Heavy Atom Count30
Formal Charge0
Complexity787
Isotope Atom Count0
Defined Atom Stereocenter Count6
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Examined for treatment of adrenocortical insufficiency especially in multiple sclerosis, congenital cerebral palsy, polyarteritis nodosa, and rheumatoid arthritis. Currently only approved in treating cats and dogs for the treatment of Addison's disease.


For use as replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism (Addison's disease).


5 Pharmacology and Biochemistry
5.1 Pharmacology

Used to treat adrenocortical insufficiency, desoxycorticosterone pivalate is a mineralocorticoid hormone and an analogue of desoxycorticosterone. It primarily acts on the metabolism of sodium, potassium and water. When the drug is given, there is decreased excretion of sodium accompanied by increased excretion of potassium; the concentration of sodium in the blood is thereby increased whereas that of potassium is decreased. There is a concomitant increase in the volume of blood and extracellular fluids, with a fall in hematocrit. It increases the rate of renal tubular absorption of sodium.


5.2 ATC Code

QH02AA03


5.3 Mechanism of Action

Desoxycorticosterone Pivalate binds to the mineralocorticoid receptor. Mineralocorticoids are a family of steroids, secreted by the adrenal cortex, necessary for the regulation of a number of metabolic processes including electrolyte regulation. Desoxycorticosterone pivalate exerts its effect through its interaction with the mineralocorticoid receptor (MR), whereby it reacts with the receptor proteins to form a steroid-receptor complex. This complex moves into the nucleus, where it binds to chromatin which results in genetic transcription of cellular DNA to messenger RNA. The steroid hormones appear to induce transcription and synthesis of specific proteins, which produce the physiological effects seen after administration.


Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Thickeners and Stabilizers

read-more
read-more

Solubilizers

read-more
read-more

Rheology Modifiers

read-more
read-more

Coating Systems & Additives

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Emulsifying Agents

read-more
read-more

Topical

read-more
read-more

Parenteral

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Market Place

Do you need sourcing support? Ask us

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty